In vitro Development of Controlled-Release Nanoniosomes for Improved Delivery and Anticancer Activity of Letrozole for Breast Cancer Treatment
Open accessThe DOI matches its Crossref record; 85 of the 86 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Introduction: Breast cancer is among the most prevalent mortal cancers in women worldwide. In the present study, an optimum formulation of letrozole, letrozole-loaded niosome, and empty niosome was developed, and the anticancer effect was assessed in in vitro MCF-7, MCF10A and MDA-MB-231 breast cancer cell lines. Materials and Methods: Various niosomal formulations of letrozole were fabricated through thin-film hydration method and characterized in terms of size, polydispersity index (PDI), morphology, entrapment efficiency (EE%), release kinetics, and stability. Optimized niosomal formulation of letrozole was achieved by response surface methodology (RSM). Antiproliferative activity and the mechanism were assessed by MTT assay, quantitative real-time PCR, and flow cytometry. Furthermore, cellular uptake of optimum formulation was evaluated by confocal electron microscopy. Results: The formulated letrozole had a spherical shape and showed a slow-release profile of the drug after 72 h. The size, PDI, and eEE% of nanoparticles showed higher stability at 4°C compared with 25°C. The drug release from niosomes was in accordance with Korsmeyer–Peppa’s kinetic model. Confocal microscopy revealed the localization of drug-loaded niosomes in the cancer cells. MTT assay revealed that all samples exhibited dose-dependent cytotoxicity against breast cancer cells. The IC 50 of mixed formulation of letrozole with letrozole-loaded niosome (L + L 3 ) is the lowest value among all prepared formulations. L+L 3 influenced the gene expression in the tested breast cancer cell lines by down-regulating the expression of Bcl 2 gene while up-regulating the expression of p53 and Bax genes. The flow cytometry results revealed that L + L 3 enhanced the apoptosis rate in both MCF-7 and MDA-MB-231 cell lines compared with the letrozole (L), letrozole-loaded niosome (L 3 ), and control sample. Conclusion: Results indicated that niosomes could be a promising drug carrier for the delivery of letrozole to breast cancer cells. Graphical Abstract: Keywords: breast cancer, niosome, letrozole, drug delivery system, anticancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Haseli, S., Pourmadadi, M., Samadi, A., Yazdian, F. A., Abdouss, M., Rashedi, H., & Nigjeh, M. N. (2022) · Biotechnology Progress · doi:10.1002/btpr.3280 · Cited by 83 · cited 1×
“Development of targeted drug delivery systems (DDSs) has received extensive attention.(12,13,14,15) The combination of medicine and nanotechnology has modified multifunctional nanocarriers that can be loaded with different drugs.”
BackgroundRetractedBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“Introduction Over the past decade a surge of breast cancer incidence was observed among the female population.(1,2) Most breast cancers are hormone-dependent and estrogen is a mediator hormone in progression and metastasis of tumor cells.”
BackgroundRe-epithelialization and immune cell behaviour in an ex vivo human skin model
Rakita, A., Nikolić, N., Mildner, M., Matiasek, J., & Elbe-Bürger, A. (2020) · Scientific Reports · doi:10.1038/s41598-019-56847-4 · Cited by 8,228
Mechanisms of solute release from porous hydrophilic polymers
Korsmeyer, R. W., Gurny, R., Doelker, E., Buri, P., & Peppas, N. A. (1983) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(83)90064-9 · Cited by 5,258 · cited 1×
“85) indicate that drug release is based on Fickian diffusion release.(65,66) More stability of the niosomes stored at 4 ± 2°C is possibly due to less mobility of bilayer at this temperature.”
BackgroundLive or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
Kinetic modeling on drug release from controlled drug delivery systems.
Dash, S., Murthy, P. N., Nath, L., & Chowdhury, P. (2010) · PubMed · Cited by 2,733
Endosomal escape pathways for delivery of biologicals
Varkouhi, A. K., Scholte, M., Storm, G., & Haisma, H. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.004 · Cited by 1,561 · cited 1×
“Polymeric nanoparticles penetrate into cancer cells, diffuse in the cytoplasm, and escape from endosomal degradation.(56,84,85) Another study revealed that nanoparticles of mesoporous silica could enter the cells and remain for a long time which is enough to allow the release of drug from formulation.”
BackgroundNonionic surfactant vesicular systems for effective drug delivery—an overview
Kumar, G. P., & Rajeshwarrao, P. (2011) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2011.09.002 · Cited by 644
Dombernowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., Bezwoda, W., Gardin, G., Gudgeon, A., Morgan, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.453 · Cited by 638 · cited 1×
“5 mg/day dosage of letrozole was associated with poorer response rates in this study.(76) In another study which developed and evaluated the effect of letrozole-loaded hyaluronic acid/chitosan-coated poly(d,l-lactide-co-glycolide) nanoparticles on 24 female albino mice (20–25 g) it was found that 300 mg/kg of the letr…”
ResultVaseva, A. V., & Moll, U. M. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2008.10.005 · Cited by 618
Research works printed but not linked: 17
- Bray, 2018, CA, 68, 394
- Sarhadi, 2020, Trans Appl Sci, 6, 309
- Cohen, 2002, Clin Cancer Res, 8, 665
- 2020, Niosomal Delivery of Simvastatin to MDA-MB-231 Cancer Cells
- Azizi, 2015, J Chem Pharm Res, 7, 423
- Nowroozi, 2018, Iran J Pharm Sci, 17, 1
- 2020, Optimization and Characterization of Tannic Acid Loaded Niosomes for Enhanced Antibacterial and Anti-Biofilm Activities
- Dash, 2010, Acta Pol Pharm, 67, 217
- 2015, Strategies to Modify the Drug Release from Pharmaceutical Systems
- Sadeghi, 2020, Pharm Chem J, 53, 1, 10.1007/s11094-020-02100-6 · DOI
- Lawrence, 1996, STP Pharma Sci, 6, 49
- Seras-Cansell, 1996, STP Pharma Sci, 6, 12
- Pardakhty, 2011, DARU J Pharm Sci, 19, 404
- Trunet, 1993, J Clin Endocrinol Metab, 77, 319, 10.1210/jcem.77.2.8345034 · doi:10.1210/jcem.77.2.8345034 · Paper page
- Radwan, 2021, J Pharm Innov, 17, 1
- Khorani, 2022, J. Alzheimer’s Dis, 1
- Amiri, 2016, Asian Pac J Cancer Prev, 17, 3835
Cited by
Dastneshan, A., Rahiminezhad, S., Mezajin, M. N., Jevinani, H. N., Akbarzadeh, I., Abdihaji, M., Qahremani, R., Jahanbakhshi, M., Lalami, Z. A., Heydari, H., et al. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.140544 · Cited by 120
Self-citationBazzazan, S., Moeinabadi‐Bidgoli, K., Lalami, Z. A., Bazzazan, S., Mehrarya, M., Yeganeh, F. E., Hejabi, F., Akbarzadeh, I., Noorbazargan, H., Jahanbakhshi, M., et al. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.104009 · Cited by 74
Self-citationCurcumin-Incorporated Biomaterials: In silico and in vitro evaluation of biological potentials
Torbat, N. A., Akbarzadeh, I., Rezaei, N., Moghaddam, Z. S., Bazzazan, S., & Mostafavi, E. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215233 · Cited by 35
Self-citationBadivi, S., Kazemi, S., Eskandarisani, M., Moghaddam, N. A., Mesbahian, G., Karimifard, S., & Afzali, E. (2024) · Scientific Reports · doi:10.1038/s41598-024-68156-6 · Cited by 29
Khaledizadeh, E., Tafvizi, F., & Jafari, P. (2023) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2023.127357 · Cited by 29
Carmona‐Sarabia, L., Vélez, G. Q., Mojica-Vázquez, D., Escalera‐Joy, A. M., Esteves-Vega, S., Peterson, E. A., & López-Mejías, V. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c05421 · Cited by 25
Akbarzadeh, I., Rezaei, N., Bazzazan, S., Mezajin, M. N., Mansouri, A., Karbalaeiheidar, H., Ashkezari, S., Moghaddam, Z. S., Lalami, Z. A., & Mostafavi, E. (2023) · Biomaterials Advances · doi:10.1016/j.bioadv.2023.213384 · Cited by 23
Self-citationRezaei, N., Arki, M. K., Miri-Lavasani, Z., Solhi, R., Khoramipour, M., Rashedi, H., Aghdaei, H. A., Hossein‐Khannazer, N., Mostafavi, E., & Vosough, M. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.04.016 · Cited by 23
Self-citationAbdihaji, M., Chegeni, M. M., Hadizadeh, A., Farrokhzad, N., Kheradmand, Z., Fakhrfatemi, P., Faress, F., Moeinabadi‐Bidgoli, K., Noorbazargan, H., & Mostafavi, E. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s401725 · Cited by 23
“Another beneficial facet of herbal medicine compared to classical chemotherapy is its limited acute or chronic toxic side effects.(9,10) Although known to be less toxic, herbal medicine could be overdosed systematically to achieve appropriate pharmacodynamics, leading to unwanted toxicities.”
BackgroundSelf-citationHashemi, A., Hayat-Gheibi, S. R., & Baghbani‐Arani, F. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105515 · Cited by 17
Abu‐Zaid, A., Gari, A. M., Sabban, H., Alshahrani, M. S., Khadawardi, K. A., Badghish, E., AlSghan, R., Bukhari, I. A., Alyousef, A., Abuzaid, M., et al. (2023) · Reproductive Sciences · doi:10.1007/s43032-023-01404-8 · Cited by 21
“Letrozole is an aromatase inhibitor that was initially prescribed to postmenopausal women with hormone-dependent breast cancer [20].”
Toxicity of Carboplatin-Niosomal Nanoparticles in a Brain Cancer Cell Line
Abbasi, M., Reihanisaransari, R., Poustchi, F., Hheidari, A., Ghanbarikondori, P., Salehi, H., Salehi, V., Izadkhah, M., Moazzam, F., & Allahyartorkaman, M. (2023) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2023.24.11.3985 · Cited by 14
“The literature contains various formulations of niosomes incorporating chemotherapeutics (Ahmadi, Seraj et al. 2022, Honarvari, Karimifard et al. 2022 study, niosomes loaded with melittin were investigated for the treatment of breast cancer.”
BackgroundAn update on nanoformulations with FDA approved drugs for female reproductive cancer
Raj, M., Meena, A., Seth, R., Mathur, A., & Luqman, S. (2025) · Journal of Microencapsulation · doi:10.1080/02652048.2025.2474457 · Cited by 13
Rouhani, M., Valizadeh, V., Bakhshandeh, H., Hosseinzadeh, S. A., Molasalehi, S., Atyabi, S. M., & Norouzian, D. (2023) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-023-12734-7 · Cited by 10
Bakhtiari, R., Shiri, M., Mohammadi, M. R., Pourmand, M. R., Mirzaie, A., & Taghiabadi, Z. (2025) · Revista Argentina de Microbiología · doi:10.1016/j.ram.2024.10.001 · Cited by 9
Ronaghi, M., Hajibeygi, R., Ghodsi, R., Eidi, A., & Bakhtiari, R. (2024) · AMB Express · doi:10.1186/s13568-024-01689-1 · Cited by 11
Davarpanah, F., Safari, J., & Masaeli, E. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214527 · Cited by 8
Hashemi, A., Rezaei, N., Shirkavand, F., Gholizadeh, F., & Baghbani‐Arani, F. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.03.008 · Cited by 8
AbouHussein, L. H., Shalaby, R. A., Ahmed, S., & Fatouh, A. M. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108528 · Cited by 7
Letrozole-Loaded Nano-formulations as a Drug Delivery System for Cancer Therapy: Recent Developments
Pourmadadi, M., Hosseini, S. M., Parvaneh, S., Ahmadi, H., Abdouss, M., Rahdar, A., Ghotekar, S. K., & Tehrani, F. S. (2023) · BioNanoScience · doi:10.1007/s12668-023-01196-w · Cited by 9
Self-citationElsori, D. H., Pandey, P., Rab, S. O., Alharbi, A., Sahoo, S., Pandey, S., Srivastava, M., Lakhanpal, S., Saeed, M., & Khan, F. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s520580 · Cited by 6
Pinto, M. B., Pires, P. C., Correia, M., Moço, G., Sousa‐Oliveira, I., Sousa, M. J., Calhelha, R. C., Vilas‐Boas, M., Falcão, S. I., Mazzola, P. G., et al. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00253 · Cited by 7
Oral nano-formulations for endocrine therapy of endometrioid adenocarcinomas
Cui, M., Liu, Y., Liu, Y., Li, T., Chen, X., & Liu, D. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117328 · Cited by 7
Naserkhaki, R., Zarrabi, A., Hashemi, M., Crawford, A. D., Bakhshandeh, H., Chiani, M., Fotouhi, A., Piryaei, A., Tahamtani, Y., & Vosough, M. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.114830 · Cited by 3
Self-citationPardines, A. C., Ginés, G. L., García-Orueta, G., & Trocóniz, I. F. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107103 · Cited by 2
Yeganeh, F. E., Ghafuri, H., & Azizi, M. (2024) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-024-04985-5 · Cited by 2
“Niosomes are actually vesicles that have a blue core and lipid layers [22].”
Zargarani, N., Kavousi, M., & Aliasgari, E. (2025) · BMC Cancer · doi:10.1186/s12885-025-14249-y · Cited by 2
“Scanning was performed on the samples between 4000 and 400 cm − 1 [23].”
Joni, H. A., Esmaeili, F., Landi, B., Bayat, E., Bakhshandeh, H., Talebkhan, Y., Barkhordari, F., Sadeghi, S., Nematollahi, L., & Negahdari, B. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010316435240806053230 · Cited by 1
Yeganeh, F. E., & Azizi, M. (2025) · Journal of Sol-Gel Science and Technology · doi:10.1007/s10971-025-06797-3 · Cited by 1
Mostafa, M. M., Mosallam, S., Taweel, M. M. E., Amin, M. M., & El‐Halim, S. M. A. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126751 · Cited by 1
Bazargan, E., Ashrafi, F., & elham, S. T. (2024) · مجله علمی دانشگاه علوم پزشکی رفسنجان · doi:10.61186/jrums.23.4.207
Vesicular Nanosystem as a Promising Platform for the Management of Cancer
Kamel, R., Darwish, A. B., Youness, R. A., & Basha, M. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_329
Scientific mapping of the use of lecithin in breast cancer therapy
Leite, G. C. C., Leite, G. C. C. C., & Dendasck, C. V. (2024) · Revista Científica Multidisciplinar Núcleo do Conhecimento · doi:10.32749/nucleodoconhecimento.com.br/fisica-en/scientific-mapping
Trivedi, M., Patel, A. S., Shukla, N., & Kapoor, A. (2025) · Current Nanomedicine · doi:10.2174/0124681873349887250211064235
sheikhhosseini, M., Soltanian, S., & Mohamadi, N. (2025) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2025.2545486
The mechanisms and applications of endocytosis and exocytosis in breast cancer therapy
Xu, M., & Duan, X. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0059
“…雌激素受体调 节剂 他莫昔芬( Tamoxifen ) 371.5 Da √ [24] 有机阴离子转运 多肽 OATP1B1 [25] √ [26] 泌 治 疗 芳香化酶抑制 剂 来曲唑( Letrozole ) 285.3Da √ [27] 有机阴离子转运 多肽 OATP1B [28] √ [29] 雌激素受体降 解剂 氟维司群( Fulvestrant ) 606.8 Da √ [30] 暂无 √ [31] 靶 向 药 HER2 靶向药 HER2 靶向( ADCC ) 145~148kDa [32,33] 依赖与细胞表面 HER2 结合发挥作用 HER2 靶向( ADC )…”
InfluentialNasr, Z. S., Hasanien, Y. A., Mosleh, M. A., & Aboumanei, M. H. (2026) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2026.112475
Advancing cancer therapeutics: MicroRNA delivery via nano-niosomes
Kaur, A. P., Bhuker, S., Saini, A. K., & Saini, R. V. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108198 · Cited by 1
Antimicrobial activity of echinacea-loaded metal-organic framework against Pseudomonas aeruginosa
Ashrafi, F., Moulavi, P., Jamalipanah, Z., Jafari, M., Zomorodi, A. R., & Asadi, S. (2026) · AMB Express · doi:10.1186/s13568-026-02073-x
El-Habashy, S. S., Helal, A. I., Elzeiny, D. A., Haikal, A., Salem, A. E., Shukry, M., Ebrahim, H. A., Althobaiti, S. A., & Abdallah, D. N. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103707
Developing Mixed Micelle Delivery Systems for Aromatase Inhibitors
Vermani, S., Singh, P., Kaur, V., Bedi, N., Jaglan, S., Kaur, S., & Ahmad, S. S. (2026) · ACS Omega · doi:10.1021/acsomega.6c01669
Alenazi, N. A., Khired, Z., Shubaily, H. M., Hazzazi, Y., Somailie, M., Alamri, A. A., Alhejely, A., Alnashiri, H. M., Sumayli, M., & Salama, S. A. (2026) · Journal of Liposome Research · doi:10.1080/08982104.2026.2714171
Vignesh, N., Kayal, P., ALLIMALARKODI, S., & Mishra, M. K. (2026) · Human Gene · doi:10.1016/j.humgen.2026.201603
Ashrafi, F., Khalili, G., Moulavi, P., Jafari, M., Asadi, S., Jozaie, S., & Jafari, R. (2026) · Journal of Microencapsulation · doi:10.1080/02652048.2026.2731041
Metadata
- Authors
- Ahmadi, S., Seraj, M., Chiani, M., Hosseini, S., Bazzazan, S., Akbarzadeh, I., Saffar, S., & Mostafavi, E.
- Affiliations
- Pasteur Institute of Iran (IR)
- Shahid Beheshti University (IR)
- Stanford Medicine (US)
- Corresponding author
- Mostafavi, Ebrahim
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2022-12
- Volume
- Volume 17
- Pages
- 6233-6255
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- PMC
- PMC9753765
- OpenAlex
- W4311260165
- Cited by
- 44
- References
- 85
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 10 · 2023: 10 · 2022: 2
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Nanomedicine (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Pasteur Institute of Iran
- National Institute of Biomedical Imaging and Bioengineering (T32EB009035)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- letrozole, niosomes, breast cancer, controlled drug release, anticancer drug delivery, apoptosis, Bcl-2, p53, Bax, MCF-7 cells, MDA-MB-231 cells, MCF10A cells, cytotoxicity, Korsmeyer-Peppas kinetics, encapsulation efficiency, cellular uptake
- MeSH terms
- Letrozole, Breast Neoplasms, Delayed-Action Preparations, Female, Humans, Liposomes, MCF-7 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.